Home/Pipeline/BNT116

BNT116

Non-small cell lung cancer (NSCLC)

Phase 2ActiveN/A

Key Facts

Indication

Non-small cell lung cancer (NSCLC)

Phase

Phase 2

Status

Active

Company

BioNTech

About BioNTech

BioNTech SE is a pioneering German biotechnology company founded in 2008 with a mission to translate immunological science into life-saving immunotherapies and vaccines. Its historic achievement was the co-development and global commercialization of the first approved mRNA-based COVID-19 vaccine, Comirnaty, with Pfizer, which validated its core platform and provided substantial financial and operational resources. The company is now strategically deploying its validated mRNA technology, alongside complementary modalities like bispecific antibodies, to build a deep and diversified oncology pipeline while advancing next-generation vaccines for infectious diseases.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other Non-small cell lung cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active